Trials / Completed
CompletedNCT01302587
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
A Prospective, Open Label, Assessment of [an Albuterol] Hydrofluoroalkane (HFA) Metered Dose Inhaler MDI Integrated Dose Counter
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 306 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albuterol | Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study. |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2011-02-24
- Last updated
- 2012-06-22
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01302587. Inclusion in this directory is not an endorsement.